Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Niraparib|DRUG: Placebo
Sponsor: GlaxoSmithKline